# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophagea...
The recommendation comes after a former Amazon employee accused the Seattle-based company of selling technology to Russia.
- CNBC